Tuesday, May 30, 2023
Sun Pharma and Philogen have recently entered into an exclusive distribution, licence, and supply agreement. This strategic partnership aims to facilitate the commercialisation of the innovative speciality product, NIDLEGY™, in the regions of Europe, Australia, and New Zealand.
This agreement likely includes provisions regarding the marketing, distribution, and promotion of Nidlegy™ within the specified territories.
The collaboration between Philogen and Sun Pharma in the oncodermatology space sounds significant. It aims to focus on the commercialisation of Nidlegy™, an immunotherapy that holds promise for improving therapeutic options for patients dealing with melanoma and non-melanoma skin cancers. These conditions are considered high-risk with unmet medical needs, meaning there is a lack of effective treatment options currently available.
Both companies share a strong dedication to advancing and bringing Nidlegy™ to market, ensuring its widespread accessibility to patients who can potentially derive significant benefits from its use.
With the anticipated inclusion of Nidlegy™ into the current Odomzo™ portfolio, establishes a strong position to deliver comprehensive solutions for patients dealing with a wide range of skin cancers at different stages of the disease.
